住院患者适当使用促红细胞生成剂。

Innovations in pharmacy Pub Date : 2024-11-26 eCollection Date: 2024-01-01 DOI:10.24926/iip.v15i4.6284
Chenghao Cui, Timothy Nguyen, Mohammad A Rattu
{"title":"住院患者适当使用促红细胞生成剂。","authors":"Chenghao Cui, Timothy Nguyen, Mohammad A Rattu","doi":"10.24926/iip.v15i4.6284","DOIUrl":null,"url":null,"abstract":"<p><p><i>Background</i>: Anemia is a significant global public health issue, and is associated with lethargy, weakness, tiredness, and shortness of breath. Erythropoiesis stimulating agents (ESAs) are recombinant/synthetic erythropoietin and can increase hemoglobin (Hb) levels. There are increased risks of cardiovascular events and death associated with the use of ESAs when raising Hb levels above 12 g/dL. <i>Methods:</i> The objective was to assure safety and appropriate use of ESA. We performed a baseline assessment via a retrospective chart review, including patients who recently received an inpatient dose of an ESA within Mount Sinai Hospital (MSH) from November 1, 2015 (after MSH ESA guideline revision) to August 1, 2023. All adult patients who received an ESA (originator or biosimilar products) during hospitalization were included. Data collection was in reverse chronology, and the most recent dose administered to each unique patient was collected. <i>Results</i>: If an ESA dose was dispensed when the Hb was less than the upper limit of the target Hb for the specific indication, this was considered appropriate use. Based on data from June 15 to August 1, 2023 (~47 days of inpatient utilization), for the primary outcome, 169 out of 171 doses (98.8%) met the predefined criteria for appropriateness. One dose was dispensed when the Hb was 11.1 g/dL to a patient on renal replacement therapy, and one dose was dispensed when the Hb was 13.8 g/dL to a surgical patient who refused blood transfusions. Among secondary outcomes of interest, there was a difference in blood transfusions administered in critical versus non-critical care settings. <i>Conclusion</i>: Inpatient use of ESA at MSH was appropriate when looking at Hb targets. There are currently no formal order sets, service-line restrictions, or additional chairperson approvals needed at MSH. Despite this, there remained significant adherence to prevailing Hb targets, reflecting provider and pharmacy teams' knowledge and awareness of contemporary best practices.</p>","PeriodicalId":501014,"journal":{"name":"Innovations in pharmacy","volume":"15 4","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12090088/pdf/","citationCount":"0","resultStr":"{\"title\":\"Appropriate Use of Inpatient Erythropoiesis Stimulating Agents.\",\"authors\":\"Chenghao Cui, Timothy Nguyen, Mohammad A Rattu\",\"doi\":\"10.24926/iip.v15i4.6284\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p><i>Background</i>: Anemia is a significant global public health issue, and is associated with lethargy, weakness, tiredness, and shortness of breath. Erythropoiesis stimulating agents (ESAs) are recombinant/synthetic erythropoietin and can increase hemoglobin (Hb) levels. There are increased risks of cardiovascular events and death associated with the use of ESAs when raising Hb levels above 12 g/dL. <i>Methods:</i> The objective was to assure safety and appropriate use of ESA. We performed a baseline assessment via a retrospective chart review, including patients who recently received an inpatient dose of an ESA within Mount Sinai Hospital (MSH) from November 1, 2015 (after MSH ESA guideline revision) to August 1, 2023. All adult patients who received an ESA (originator or biosimilar products) during hospitalization were included. Data collection was in reverse chronology, and the most recent dose administered to each unique patient was collected. <i>Results</i>: If an ESA dose was dispensed when the Hb was less than the upper limit of the target Hb for the specific indication, this was considered appropriate use. Based on data from June 15 to August 1, 2023 (~47 days of inpatient utilization), for the primary outcome, 169 out of 171 doses (98.8%) met the predefined criteria for appropriateness. One dose was dispensed when the Hb was 11.1 g/dL to a patient on renal replacement therapy, and one dose was dispensed when the Hb was 13.8 g/dL to a surgical patient who refused blood transfusions. Among secondary outcomes of interest, there was a difference in blood transfusions administered in critical versus non-critical care settings. <i>Conclusion</i>: Inpatient use of ESA at MSH was appropriate when looking at Hb targets. There are currently no formal order sets, service-line restrictions, or additional chairperson approvals needed at MSH. Despite this, there remained significant adherence to prevailing Hb targets, reflecting provider and pharmacy teams' knowledge and awareness of contemporary best practices.</p>\",\"PeriodicalId\":501014,\"journal\":{\"name\":\"Innovations in pharmacy\",\"volume\":\"15 4\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-11-26\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12090088/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Innovations in pharmacy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.24926/iip.v15i4.6284\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Innovations in pharmacy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.24926/iip.v15i4.6284","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

背景:贫血是一个重要的全球公共卫生问题,与嗜睡、虚弱、疲倦和呼吸短促有关。促红细胞生成素(ESAs)是重组/合成促红细胞生成素,可以增加血红蛋白(Hb)水平。当Hb水平高于12 g/dL时,使用esa会增加心血管事件和死亡的风险。方法:目的是确保ESA的安全、合理使用。我们通过回顾性图表回顾进行了基线评估,包括2015年11月1日(MSH ESA指南修订后)至2023年8月1日在西奈山医院(MSH)接受住院剂量ESA的患者。所有在住院期间接受了ESA(原料药或生物仿制药)的成年患者被纳入研究。数据的收集是按逆时间顺序进行的,并收集每个患者最近的剂量。结果:如果在Hb低于特定适应症的靶Hb上限时分配ESA剂量,则认为这是适当的使用。根据2023年6月15日至8月1日的数据(住院使用约47天),对于主要结局,171剂中有169剂(98.8%)符合预定义的适当性标准。当接受肾脏替代治疗的患者Hb为11.1 g/dL时,分配一剂,当Hb为13.8 g/dL时,分配一剂给拒绝输血的手术患者。在次要结局中,在重症监护环境中输血与非重症监护环境中输血存在差异。结论:住院患者在MSH检查Hb靶时使用ESA是合适的。目前,MSH不需要正式的订单集、服务线限制或额外的主席批准。尽管如此,仍然有显着遵守流行的Hb目标,反映了提供者和药房团队对当代最佳实践的知识和意识。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Appropriate Use of Inpatient Erythropoiesis Stimulating Agents.

Background: Anemia is a significant global public health issue, and is associated with lethargy, weakness, tiredness, and shortness of breath. Erythropoiesis stimulating agents (ESAs) are recombinant/synthetic erythropoietin and can increase hemoglobin (Hb) levels. There are increased risks of cardiovascular events and death associated with the use of ESAs when raising Hb levels above 12 g/dL. Methods: The objective was to assure safety and appropriate use of ESA. We performed a baseline assessment via a retrospective chart review, including patients who recently received an inpatient dose of an ESA within Mount Sinai Hospital (MSH) from November 1, 2015 (after MSH ESA guideline revision) to August 1, 2023. All adult patients who received an ESA (originator or biosimilar products) during hospitalization were included. Data collection was in reverse chronology, and the most recent dose administered to each unique patient was collected. Results: If an ESA dose was dispensed when the Hb was less than the upper limit of the target Hb for the specific indication, this was considered appropriate use. Based on data from June 15 to August 1, 2023 (~47 days of inpatient utilization), for the primary outcome, 169 out of 171 doses (98.8%) met the predefined criteria for appropriateness. One dose was dispensed when the Hb was 11.1 g/dL to a patient on renal replacement therapy, and one dose was dispensed when the Hb was 13.8 g/dL to a surgical patient who refused blood transfusions. Among secondary outcomes of interest, there was a difference in blood transfusions administered in critical versus non-critical care settings. Conclusion: Inpatient use of ESA at MSH was appropriate when looking at Hb targets. There are currently no formal order sets, service-line restrictions, or additional chairperson approvals needed at MSH. Despite this, there remained significant adherence to prevailing Hb targets, reflecting provider and pharmacy teams' knowledge and awareness of contemporary best practices.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信